Transforming growth factor-beta receptor and bone morphogenetic protein-related receptor (TGFBR/BMPR)

The Transforming growth factor-beta (TGF-beta) and bone morphogenetic protein (BMP) receptor family consists of transmembrane serine/threonine kinases that mediate signaling for a diverse group of ligands, including TGF-beta isoforms, BMPs, activins, and growth differentiation factors (GDFs) [2, 10]. These receptors function as heterotetrameric complexes typically comprising two type I receptors (activin receptor-like kinases, ALKs) and two type II receptors [2, 19]. Upon ligand binding, the type II receptor phosphorylates the type I receptor, which then activates intracellular SMAD proteins—SMAD2/3 for the TGF-beta/activin branch and SMAD1/5/8 for the BMP branch—to regulate gene transcription [5, 14]. This signaling network is essential for embryonic development, bone formation, tissue repair, and immune homeostasis [1, 16]. Dysregulation of these receptors is implicated in a wide range of diseases, including cancer (where they exhibit dual roles as tumor suppressors and promoters), tissue fibrosis, and cardiovascular disorders like pulmonary arterial hypertension [3, 11, 22]. Therapeutic interventions include small molecule kinase inhibitors, neutralizing antibodies, and ligand traps, although clinical progress has been tempered by safety concerns such as cardiotoxicity and skin-related adverse events [3, 8, 15].

Other names

Transforming growth factor-beta superfamily receptorsTGF-beta/BMP receptorsActivin receptor-like kinasesALKsSerine/threonine-protein kinase receptors

Inhibition of type I receptor (ALK) kinase activity, ligand neutralization via monoclonal antibodies, and ligand trapping using soluble receptor-Fc fusion proteins.